OGI Earnings Date: Dec 15, 2026 (Estimated) — Organigram Global Inc. Common Shares
XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is OGI's next earnings date?
Organigram Global Inc. Common Shares (OGI) is expected to report Q4 2026 earnings on Tuesday, December 15, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.02 on revenue of $85.4M.
How did OGI do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q3 2026), Organigram Global Inc. Common Shares posted EPS of $0.56 versus the -$0.01 estimate, a beat of 5680.0%. Revenue was $76.4M against a $68.2M estimate. The stock's 1-day post-earnings move was +17.1%.
How much does OGI stock move after earnings?
OGI beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.2% (up or down) in the day after earnings.
About Organigram Global Inc. Common Shares
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q3 2026 | -0.01 | 0.56 | +5680.00% | $76.4M | ✅ Beat | +17.14% | +16.67% | +4.76% |
| 2026-05-12 | Q2 2026 | -0.01 | -0.01 | +50.00% | $43.6M | ✅ Beat | -15.27% | -19.47% | -19.08% |
| 2026-02-10 | Q1 2026 | -0.01 | 0.10 | +1100.00% | $45.6M | ✅ Beat | -12.58% | -20.13% | -5.03% |
| 2025-12-16 | Q4 2025 | -0.01 | -0.20 | -1950.00% | $58.2M | ❌ Miss | +8.89% | +6.67% | -11.67% |
| 2025-08-13 | Q3 2025 | -0.01 | -0.03 | -240.00% | $51.1M | ❌ Miss | +0.63% | -4.40% | +4.40% |
| 2025-02-11 | Q1 2025 | -0.03 | -0.14 | -366.67% | $30.6M | ❌ Miss | -16.76% | -21.39% | -41.04% |
| 2024-12-18 | Q4 2024 | -0.03 | -0.08 | -166.67% | $32.8M | ❌ Miss | -8.70% | -3.11% | -4.35% |
| 2024-08-13 | Q3 2024 | -0.05 | 0.02 | +140.00% | $30.0M | ✅ Beat | +25.69% | +38.19% | +29.17% |
Showing last 8 quarters.
Revenue by segment & region
By segment
FY2025 · $38.2M total · annual
| Segment | Share | Revenue | YoY | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| International Business To Business | 68.9% | $26.3M | +172.9% | $386K | $15.1M | $9.7M | $26.3M |
| Wholesale To Licensed Producers Revenue | 24.5% | $9.4M | +76.2% | $2.1M | $1.3M | $5.3M | $9.4M |
| Direct To Patient Medical Revenue | 6.3% | $2.4M | +38.6% | $8.7M | $7.9M | $1.7M | $2.4M |
| Other Revenue | 0.4% | $142K | +46.4% | $202K | $115K | $97K | $142K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.